The median overall survival in patients with advanced metastatic prostate cancer, who were treated with OGX-011 plus docetaxel in a randomized phase II trial, was 23.8 months compared to 16.9 months for patients treated with docetaxel alone, a 6.9 month observed survival advantage for the OGX-011 arm.
Dr. Chi, Principal Investigator of the NCIC-CTG sponsored trial at ASCO, said, A 6.9 month median overall survival difference would represent a significant improvement over the current standard docetaxel therapy.
Docetaxel was approved in 2004 based on a 2.4 month survival advantage in advanced prostate cancer. The consistent results in favor of the OGX-011 treatment arm in this trial are a clear indication that Phase 3 trials are warranted, he added.